Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105
Jefferies Keeps Their Buy Rating on Intra-Cellular Therapies (ITCI)
Intra-Cellular Therapies Price Target Maintained With a $130.00/Share by Cantor Fitzgerald
Express News | Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $130 Price Target
Intra-Cellular Therapies' (NASDAQ:ITCI) Investors Will Be Pleased With Their Fantastic 798% Return Over the Last Five Years
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
Intra-Cellular Therapies (NASDAQ:ITCI) Delivers Shareholders Fantastic 54% CAGR Over 5 Years, Surging 3.9% in the Last Week Alone
S&P 500 Futures Climb In Premarket Trading; Summit Therapeutics, Palantir Technologies Lead
Piper Sandler Ups Intra-Cellular to Overweight, Cites Caplyta Potential
This Robinhood Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday
Intra-Cellular Therapies Raised to Overweight From Neutral by Piper Sandler
Piper Sandler Upgrades Intra-Cellular Therapies(ITCI.US) to Buy Rating, Raises Target Price to $92
Intra-Cellular Therapies(ITCI.US) Officer Sells US$5.09 Million in Common Stock
Intra-Cellular Therapies(ITCI.US) Officer Sells US$7.05 Million in Common Stock
Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business
Intra-Cellular Therapies Insider Sold Shares Worth $9,086,738, According to a Recent SEC Filing
Intra-Cellular Therapies(ITCI.US) Officer Sells US$9.09 Million in Common Stock
Form 144 | Intra-Cellular Therapies(ITCI.US) Officer Proposes to Sell 4.01 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Aug 21, $Intra-Cellular Therapies(ITCI.US)$ Officer Mates Sharon intends to sell 53,013 shares of its common stock on Aug 21, with a total market value of approximately $4.01
Intra-Cellular Therapies Is Maintained at Overweight by JP Morgan